Abstract
Introduction
The achievement of clinical operational tolerance (COT) is still considered a major goal in the academic field of solid organ transplantation. Even COT is feasible and safe in selected cases after liver transplantation, in the clinical arena of solid organ transplantation, tolerance remains, for the most part, a concept rather than a reality.
Challenges
Although modern immunosuppression regimens have effectively handled acute rejection, nearly all organs except the liver commonly suffer chronic immunologic damage that impairs organ function, threatening patient and allograft survival. Strong arguments in favour of conducting clinical tolerance trials are the high number of grafts still lost due to chronic rejection, the burden of serious adverse effects from immunosuppressants which causes considerable cardiovascular morbidity and mortality, respectively, and the fact that sporadic tolerance can be observed in rare cases where non-adherence to immunosuppressive regimens is linked with a state of long-lasting organ tolerance. Whereas molecule-based regimens have been largely ineffective, cell-based tolerance protocols have delivered some encouraging results to achieve COT.
Discussion
In combination with donor bone marrow-derived stem cells, some encouraging results in COT development were reported lately for renal transplantation as well. However, less toxic conditioning protocols and more experience by use of cell products with regulatory properties in combination with synergizing immunosuppressive drugs is required to launch future tolerance trials for a broader spectrum of potential transplant candidates. New methods in immunomonitoring including biomarkers, microarray-based genetic tolerance signatures and functional assays may pave the way to achieve COT in upcoming clinical trials.
Similar content being viewed by others
References
Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4(3):378–383
Lerut J, Bonaccorsi-Riani E, Finet P, Gianello P (2009) Minimization of steroids in liver transplantation. Transpl Int 22(1):2–19
Demetris AJ, Lunz JG, Randhawa P, Wu T, Nalesnik M, Thomson AW (2009) Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 22(1):120–141
Orlando G, Soker S, Wood K (2009) Operational tolerance after liver transplantation. J Hepatol 50(6):1247–1257
Orlando G, Hematti P, Stratta RJ, Burke GW, Di Cocco P, Pisani F, Soker S, Wood K (2010) Clinical operational tolerance after renal transplantation current status and future challenges. Ann Surg 252(6):915–928
Svendsen UG, Aggestrup S, Heilmann C, Jacobsen N, Koch C, Larsen B, Svejgaard A, Thisted B, Petterson G (1995) Transplantation of a lobe of lung from mother-to-child following previous transplantation with maternal bone-marrow. Eur Respir J 8(2):334–337
Comerci GD, Williams TM, Kellie S (2009) Immune tolerance after total lymphoid irradiation for heart transplantation: immunosuppressant-free survival for 8 years. J Heart Lung Transplant 28(7):743–745
Weil R, Starzl TE, Porter KA, Kershaw M, Schroter GPJ, Koep LJ (1980) Renal isotransplantation without immunosuppression. Ann Surg 192(1):108–110
Burlingham WJ, Grailer AP, Fechner JH, Kusaka S, Trucco M, Kocova M, Belzer FO, Sollinger HW (1995) Microchimerism linked to cytotoxic T-lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal-transplant recipient. Transplantation 59(8):1147–1155
Trivedi HL, Mishra VV, Vanikar AV, Modi PR, Shah VR, Shah PR, Firoz A (2006) Embryonic stem cell derived and adult hematopoietic stem cell transplantation for tolerance induction in a renal allograft recipient: a case report. Transplant Proc 38(9):3103–3108
Burke GW, Ciancio G, Cirocco R, Markou M, Coker D, Roth D, Nery J, Esquenazi V, Miller J (1996) Association of interleukin-10 with rejection-sparing effect in septic kidney transplant recipients. Transplantation 61(7):1114–1116
Owens ML, Maxwell JG, Goodnight J, Wolcott MW (1975) Discontinuance of immunosuppression in renal-transplant patients. Arch Surg 110(12):1450–1451
Zoller KM, Cho SI, Cohen JJ, Harrington JT (1980) Cessation of immunosuppressive therapy after successful transplantation—a national survey. Kid Int 18(1):110–114
VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, Chin T, Kusaka S, Geissler F, Pelletier RP, Orosz CG (2000) Human allograft acceptance is associated with immune regulation. J Clin Invest 106(1):145–155
Xu Q, Lee J, Jankowska-Gan E, Schultz J, Roennburg DA, Haynes LD, Kusaka S, Sollinger HW, Knechtle SJ, VanBuskirk AM, Torrealba JR, Burlingham WJ (2007) Human CD4(+)CD25(low) adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. (vol 178, pg 3983, 2007). J Immunol 178(11):7488
Roussey-Kesler G, Giral M, Moreau A, Subra JF, Legendre C, Noel C, Pillebout E, Brouard S, Soulillou JP (2006) Clinical operational tolerance after kidney transplantation. Am J Transplant 6(4):736–746
Baeten D, Louis S, Braud C, Braudeau C, Ballet C, Moizant F, Pallier A, Giral M, Brouard S, Soulillou JP (2006) Phenotypically and functionally distinct CD8(+) lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 17(1):294–304
Brouard S, Mansfield E, Braud C, Li L, Giral M, Hsieh SC, Baeten D, Zhang M, Ashton-Chess J, Braudeau C, Hsieh F, Dupont A, Pallier A, Moreau A, Louis S, Ruiz C, Salvatierra O, Soulillou JP, Sarwal M (2007) Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 104(39):15448–15453
Burlingham WJ, Jankowska-Gan E, VanBuskirk A, Orosz CG, Lee JH, Kusaka S (2000) Loss of tolerance to a maternal kidney transplant is selective for HLA class II: evidence from trans-vivo DTH and alloantibody analysis. Hum Immunol 61(12):1395–1402
Billingham RE, Brent L, Medawar PB (1953) Actively acquired tolerance of foreign cells. Nature 172(4379):603–606
Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, McMichael J, Fung JJ, Starzl TE (1997) Weaning of immunosuppression in liver transplant recipients. Transplantation 63(2):243–249
Assy N, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN (2007) Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 83(12):1571–1576
Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, Williams R (1998) Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 27(4):926–933
Eason JD, Cohen AJ, Nair S, Alcantera T, Loss GE (2005) Tolerance: is it worth the risk? Transplantation 79(9):1157–1159
Girlanda R, Rela M, Williams R, O’Grady JG, Heaton ND (2005) Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 37(4):1708–1709
Pons JA, Yelamos J, Ramirez P, Oliver-Bonet M, Sanchez A, Rodriguez-Gago M, Navarro J, Bermejo J, Robles R, Parrilla P (2003) Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 75(7):1045–1047
Takatsuki M, Uemoto S, Inomata Y, Sakamoto S, Hayashi M, Ueda M, Kanematsu T, Tanaka K (2001) Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance. Transpl Immunol 8(4):279–286
Tisone G, Orlando G, Cardillo A, Palmieri G, Manzia TM, Baiocchi L, Lionetti R, Anselmo A, Toti L, Angelico M (2006) Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 44(4):702–709
Tryphonopoulos P, Tzakis AG, Weppler D, Garcia-Morales R, Kato T, Madariaga JR, Levi DM, Nishida S, Moon J, Selvaggi G, Regev A, Nery C, Bejarano P, Khaled A, Kleiner G, Esquenazi V, Miller J, Ruiz P, Ricordi C (2005) The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 5(3):608–613
Feng S, Ekong U, Lobritto S, Demetris A, Rosenthal P, Alonso E, Tchao N (2009) ITN029ST: immunosuppression withdrawal in pediatric recipients of parental living donor liver transplants: preliminary results of a pilot study. Am J Transplant 9:244–245
Benitez C, Lozano JJ, Martinez-Llordella M, Puig-Pey I, Lopez M, Rodriguez A, Tisone G, Pirenne J, Lerut J, Sanchez-Fueyo A (2009) Use of transcriptional biomarkers to identify liver transplant recipients who can successfully discontinue immunosuppressive therapy. Am J Transplant 9:252
Lerut J, Sanchez-Fueyo A (2006) An appraisal of tolerance in liver transplantation. Am J Transplant 6(8):1774–1780
Starzl TE, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B, Corry RJ, Jordan ML, Fontes P, Gayowski T, Bond G, Scantlebury VP, Potdar S, Randhawa P, Wu T, Zeevi A, Nalesnik MA, Woodward J, Marcos A, Trucco M, Demetris AJ, Fung JJ (2003) Tolerogenic immunosuppression for organ transplantation. Lancet 361(9368):1502–1510
Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, Bradley J, Smith K, Waldmann H (1998) Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351(9117):1701–1702
Kirk AD, Mannon RB, Kleiner DE, Swanson JS, Kampen RL, Cendales LK, Elster EA, Wakefield T, Chamberlain C, Hoffmann SC, Hale DA (2005) Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 80(8):1051–1059
Trzonkowski P, Zilvetti M, Chapman S, Wieckiewicz J, Sutherland A, Friend P, Wood KJ (2008) Homeostatic repopulation by CD28(−)CD8(+) T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 8(2):338–347
Clatworthy MR, Friend PJ, Calne RY, Rebello PRU, Hale G, Waldmann H, Watson CJE (2009) Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 87(7):1092–1095
Ciancio G, Burke GW (2008) Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 8(1):15–20
Wu ZH, Bensinger SJ, Zhang JD, Chen CQ, Yuan XL, Huang XL, Markmann JF, Kassaee A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA (2004) Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 10(1):87–92
Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL (1991) Immunological-tolerance to renal-allografts after bone-marrow transplants from the same donors. Ann Int Med 114(11):954–955
Ernst B, Lee DS, Chang JM, Sprent J, Surh CD (1999) The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 11(2):173–181
Goldrath AW, Bevan MJ (1999) Low-affinity ligands for the TCR drive proliferation of mature CD8(+) T cells in lymphopenic hosts. Immunity 11(2):183–190
Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, Mccoy KL, Swanson SJ, Mannon RB, Roederer M, Kirk AD (2005) Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5(3):465–474
Trzonkowski P, Zilvetti M, Friend P, Wood KJ (2006) Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation 82(10):1342–1351
Helg C, Chapuis B, Bolle JF, Morel P, Salomon D, Roux E, Antonioli V, Jeannet M, Leski M (1994) Renal-transplantation without immunosuppression in a host with tolerance induced by allogeneic bone-marrow transplantation. Transplantation 58(12):1420–1422
Jacobsen N, Taaning E, Ladefoged J, Kristensen JK, Pedersen FK (1994) Tolerance to an Hla-B, Dr disparate kidney allograft after bone-marrow transplantation from same donor. Lancet 343(8900):800
Butcher JA, Hariharan S, Adams MB, Johnson CP, Roza AM, Cohen EP (1999) Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant 13(4):330–335
Sorof JM, Koerper MA, Portale AA, Potter D, Desantes K, Cowan M (1995) Renal-transplantation without chronic immunosuppression after T-cell-depleted, Hla-mismatched bone-marrow transplantation. Transplantation 59(11):1633–1635
Sellers MT, Deierhoi MH, Curtis JJ, Gaston RS, Julian BA, Lanier DC, Diethelm AG (2001) Tolerance in renal transplantation after allogeneic bone marrow transplantation—6-year follow-up. Transplantation 71(11):1681–1683
Buhler LH, Spitzer TR, Sykes M, Sachs DH, Delmonico FL, Tolkoff-Rubin N, Saidman SL, Sackstein R, McAfee S, Dey B, Colby C, Cosimi AB (2002) Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 74(10):1405–1409
Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding RC, Sharma V, Fishman JA, Dey B, Ko DSC, Hertl M, Goes NB, Wong WC, Williams WW, Colvin RB, Sykes M, Sachs DH (2008) Brief report: HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 358(4):353–361
Porcheray F, Wong W, Saidman SL, De Vito J, Girouard TC, Chittenden M, Shaffer J, Tolkoff-Rubin N, Dey BR, Spitzer TR, Colvin RB, Cosimi AB, Kawai T, Sachs DH, Sykes M, Zorn E (2009) B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant 9(9):2126–2135
Bloom D, Chang Z, Pauly K, Kwun J, Fechner J, Hayes C, Samaniego M, Knechtle S (2009) BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 9(8):1835–1845
Millan TLT, Shizuru JA, Hoffmann P, Dejbakhsh-Jones S, Scandling JD, Grumet FC, Tan JC, Salvatierra O, Hoppe RT, Strober S (2002) Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 73(9):1386–1391
Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S (2008) Brief report: tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 358(4):362–368
Owen RD (1945) Immunogenetic consequences of vascular anastomoses between bovine twins. Science 102(2651):400–401
Newton WT, Anderson CB (1973) Planned preimmunization of renal-allograft recipients. Surgery 74(3):430–436
Burlingham WJ (1996) Chimerism after organ transplantation: is there any clinical significance? Clin Transplant 10(1):110–117
Schiopu A, Wood KJ (2008) Regulatory T cells: hypes and limitations. Curr Opin Organ Transplant 13(4):333–338
Sagoo P, Lombardi G, Lechler RI (2008) Regulatory T cells as therapeutic cells. Curr Opin Organ Transplant 13(6):645–653
Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, Tilanus HW, van der Laan LJW (2006) Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transplant 12(2):277–284
Bestard O, Cruzado JM, Rama I, Torras J, Goma M, Seron D, Moreso F, Gil-Vernet S, Grinyo JM (2008) Presence of FoxP3(+) regulatory T cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 119(10):2020–2026
Meloni F, Vitulo P, Bunco AM, Paschetto E, Morosini M, Cascina A, Mazzucchelli I, Ciardelli L, Ogglonni T, Fietta AM, Pozzi E, Vigano M (2004) Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation 77(5):762–766
Radhakrishnan S, Cabrera R, Schenk EL, Nava-Parada P, Bell MP, Van Keulen VP, Marler RJ, Felts SJ, Pease LR (2010) Reprogrammed FoxP3(+) T regulatory cells become IL-17(+) antigen-specific autoimmune effectors in vitro and in vivo (Retraction of vol 181, pg 3137, 2008). J Immunol 184(11):6556
Afzali B, Mitchell P, Lechler RI, John S, Lombardi G (2010) Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol 159(2):120–130
Koenen HJPM, Smeets RL, Vink PM, van Rijssen E, Boots AMH, Joosten I (2008) Human CD25(high)Foxp3(pos) regulatory T cells differentiate into IL-17-producing cells. Blood 112(6):2340–2352
Wang J, Huizinga TWJ, Toes REM (2009) De novo generation and enhanced suppression of human CD4(+)CD25(+) regulatory T cells by retinoic acid. J Immunol 183(6):4119–4126
Mitchell P, Afzali B, Lombardi G, Lechler RI (2009) The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplant 14(4):326–331
Hanson SE, Bentz ML, Hematti P (2010) Mesenchymal stem cell therapy for nonhealing cutaneous wounds. Plast Reconstr Surg 125(2):510–516
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363(9419):1439–1441
Le Blanc K, Ringden O (2007) Immunomodulation by mesenchymal stem cells and clinical experience. J Int Med 262(5):509–525
Le Blanc K, Pittenger MF (2005) Mesenchymal stem cells: progress toward promise. Cytotherapy 7(1):36–45
Crop M, Baan C, Weimar W, Hoogduijn M (2009) Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl Int 22(4):365–376
Pulendran B (2009) Modulating vaccine responses with innate immunity. Cytokine 48(1–2):5
Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Ann Rev of Immunol 21:685–711
Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S (2008) Foxp3(+) natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 105(29):10113–10118
Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S (2008) CTLA-4 control over Foxp3(+) regulatory T cell function. Science 322(5899):271–275
Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez RM, Wang YC, Pulendran B (2010) Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 329(5993):849–853
Reichardt W, Durr C, von Elverfeldt D, Juttner E, Gerlach UV, Yamada M, Smith B, Negrin RS, Zeiser R (2008) Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol 181(7):4770–4779
Stax AM, Gelderman KA, Schlagwein N, Essers MC, Kamerling SWA, Woltman AM, van Kooten C (2008) Induction of donor-specific T-cell hyporesponsiveness using dexamethasone-treated dendritic cells in two fully mismatched rat kidney transplantation models. Transplantation 86(9):1275–1282
Zhang XS, Li M, Lian DM, Zheng XF, Zhang ZX, Ichim TE, Xia XP, Huang XY, Vladau C, Suzuki M, Garcia B, Jevnikar AM, Min WP (2008) Generation of therapeutic dendritic cells and regulatory T cells for preventing allogeneic cardiac graft rejection. Clin Immunol 127(3):313–321
Reddy P, Sun YP, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, Maeda Y, Tawara I, Krijanovski O, Gatza E, Liu C, Malter C, Mascagni P, Dinarello CA, Ferrara JLM (2008) Histone deacetylase inhibition modulates indoleamine 2, 3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 118(7):2562–2573
Brem-Exner BG, Sattler C, Hutchinson JA, Koehl GE, Kronenberg K, Farkas S, Inoue S, Blank C, Knechtle SJ, Schlitt HJ, Fandrich F, Geissler EK (2008) Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol 180(1):335–349
Fandrich F, Lin XB, Chai GX, Schulze M, Ganten D, Bader M, Holle J, Huang DS, Parwaresch R, Zavazava N, Binas B (2002) Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med 8(2):171–178
Hutchinson JA, Riquelme P, Brem-Exner BG, Schulze M, Matthai M, Renders L, Kunzendorf U, Geissler EK, Fandrich F (2008) Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 21(8):728–741
Hutchinson JA, Brem-Exner BG, Riquelme P, Roelen D, Schulze M, Ivens K, Grabensee B, Witzke O, Philipp T, Renders L, Humpe A, Sotnikova A, Matthai M, Heumann A, Govert F, Schulte T, Kabelitz D, Claas FHJ, Geissler EK, Kunzendorf U, Fandrich F (2008) A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 21(8):742–754
Hutchinson JA, Roelen D, Riquelme P, Brem-Exner BG, Witzke O, Philipp T, Matthai M, Govert F, Claas FHJ, Westphal E, Kunzendorf U, Geissler EK, Fandrich F (2008) Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 21(8):808–813
Riquelme P, Govert F, Geissler EK, Fandrich F, Hutchinson JA (2009) Human transplant acceptance-inducing cells suppress mitogen-stimulated T cell proliferation. Transpl Immunol 21(3):162–165
Hutchinson JA, Riquelme P, Geissler EK, Fandrich F (2009) Macrophages driven to a novel state of activation have tolerogenic properties in kidney transplant recipients. Am J Transplant 9:657–657
Hutchinson JA, Govert F, Riquelme P, Brasen JH, Brem-Exner BG, Matthai M, Schulze M, Renders L, Kunzendorf U, Geissler EK, Fandrich F (2009) Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible. Clin Transplant 23(1):140–145
Castellaneta A, Thomson AW, Nayyar N, de Vera M, Mazariegos GV (2010) Monitoring the operationally tolerant liver allograft recipient. Curr Opin Organ Transplant 15(1):28–34
Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, Benitez C, Pons JA, Parrilla P, Ramirez P, Bruguera M, Rimola A, Sanchez-Fueyo A (2008) Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 118(8):2845–2857
Batista FD, Iber D, Neuberger MS (2001) B cells acquire antigen from target cells after synapse formation. Nature 411(6836):489–494
Lund FE, Randall TD (2010) Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 10(4):236–247
Pistoia V (1997) Production of cytokines by human B cells in health and disease. Immunol Today 18(7):343–350
Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL, Swain SL, Lund FE (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1(6):475–482
Thaunat O, Field AC, Dai JP, Louedec L, Patey N, Bloch MF, Mandet C, Belair MF, Bruneval P, Meilhac O, Bellon B, Joly E, Michel JB, Nicoletti A (2005) Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci USA 102(41):14723–14728
Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6(3):205–217
Matsushita T, Horikawa M, Iwata Y, Tedder TF (2010) Regulatory B cells (B10 Cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 185(4):2240–2252
Clatworthy MR, Watson CJE, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, Smith KGC (2009) B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 360(25):2683–2685
Sawitzki B, Bushell A, Steger U, Jones N, Risch K, Siepert A, Lehmann M, Schmitt-Knosalla I, Vogt K, Gebuhr I, Wood K, Volk HD (2007) Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 7(5):1091–1102
Karam VH, Gasquet I, Delvart V, Hiesse C, Dorent R, Danet C, Samuel D, Charpentier B, Gandjbakhch I, Bismuth H, Castaing D (2003) Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 76(12):1699–1704
Tisone G, Orlando G, Angelico M (2007) Operational tolerance in clinical liver transplantation: emerging developments. Transpl Immunol 17(2):108–113
Strober S, Lowsky RJ, Shizuru JA, Scandling JD, Millan MT (2004) Approaches to transplantation tolerance in humans. Transplantation 77(6):932–936
Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, Hayashi M, Kanematsu T, Tanaka K (2001) Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 72(3):449–454
Koshiba T, Li Y, Takemura M, Wu YL, Sakaguchi S, Minato N, Wood KJ, Haga H, Ueda M, Uemoto S (2007) Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 17(2):94–97
Li Y, Koshiba T, Yoshizawa A, Ito A, Egawa H, Sakaguchi S, Minato N, Wood KJ, Tanaka K (2004) Analysis of peripheral blood mononuclear cells in operational tolerance after living-donor liver transplantation (LDLT). Am J Transplant 4:445
Yoshizawa A, Ito A, Li Y, Koshiba T, Sakaguchi S, Wood KJ, Tanaka K (2005) The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc 37(1):37–39
Pons JA, Ramirez P, Revilla-Nuin B, Pascual D, Baroja-Mazo A, Robles R, Sanchez-Bueno F, Martinez L, Parrilla P (2009) Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant 23(3):329–336
Yoshitomi M, Koshiba T, Haga H, Li Y, Zhao X, Cheng D, Miyagawa A, Sakashita H, Tsuruyama T, Ohe H, Ueda M, Okamoto S, Egawa H, Wood K, Sakaguchi S, Manabe T, Tanaka K, Uemoto S (2009) Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 87(4):606–614
Kawamoto K, Pahuja A, Hering BJ, Bansal-Pakala P (2010) Transforming growth factor beta 1 (TGF-beta 1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3(+) Tregs. Transpl Immunol 23(1–2):28–33
Morelon E, Lefrancois N, Besson C, Prevautel J, Brunet M, Touraine JL, Badet L, Touraine-Moulin F, Thaunat O, Malcus C (2010) Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. Transpl Immunol 23(1–2):53–58
Ma AL, Qi SJ, Wang ZY, Massicotte E, Dupuis M, Daloze P, Chen HF (2009) Combined therapy of CD4(+)CD25(+) regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice. Inter Immunopharmacol 9(5):553–563
De Serres SA, Sayegh MH, Najafian N (2009) Immunosuppressive drugs and Tregs: a critical evaluation! Clinical J Am Soc Nephrol 4(10):1661–1669
Segundo DS, Fabrega E, Lopez-Hoyos M, Pons F (2007) Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors. Transplant Proc 39(7):2290–2292
Alberu J, Urrea EM (2005) Immunosuppression for kidney transplant recipients: current strategies. Rev Invest Clin 57(2):213–224
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fändrich, F. Tolerance in clinical transplantation: progress, challenge or just a dream?. Langenbecks Arch Surg 396, 475–487 (2011). https://doi.org/10.1007/s00423-011-0757-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00423-011-0757-z